Categories
Change Password!
Reset Password!
Meloxicam effectively attenuates
postsurgery pain and improves patient satisfaction in knee osteoarthritis
people undergoing knee arthroplasty.
In knee osteoarthritis people scheduled for total knee arthroplasty, meloxicam shows a good effect on alleviating postsurgery pain and enhancing patient satisfaction. However, it does not influence the safety profile, tolerance and long-term knee function recovery in such people.
Feng Hu et al. undertook this randomized, controlled, double-blind study to examine the postsurgery pain-relieving effect and tolerance of meloxicam in 128 knee osteoarthritis people undergoing total knee arthroplasty. Participants were randomly allocated to either meloxicam group (n = 65) or control group (n = 63).
The recruited people were given
meloxicam or placebo from 4 hours to 72 hours following total knee arthroplasty
and were followed up at 6 and 12 hours; days 1, 2, 3, 7; and months 1 and 3.
When compared to the control group, the meloxicam group exhibited reduced pain visual analog scale (VAS) score at rest at 12 hours, days 1, 3; reduced pain VAS score at flexion at 6 and 12 hours, days 1, 2, 3 (Figure 1); and higher patient satisfaction score on days 1,2,3.
In comparison with the control group, the meloxicam group illustrated attenuation of total and additional consumption of patient-controlled analgesia.
Regarding knee function recovery (evaluated by the hospital for special surgery knee score [HSS]), no difference at month 1 or month 3 was noted between the study groups. Furthermore, the occurrence of noxious events was comparable between the two groups. Thus, meloxicam has a remarkable potential for postoperative management of pain in people with knee osteoarthritis receiving knee arthroplasty.
Medicine (Baltimore)
Evaluation of analgesic effect, joint function recovery and safety of meloxicam in knee osteoarthritis patients who receive total knee arthroplasty: A randomized, controlled, double-blind study
Feng Hu et al.
Comments (0)